What is Seaport Therapeutics 's G&A?

Seaport Therapeutics (SPTX) reported G&A of $6.11M in Q1 2026.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Seaport Therapeutics SPTX G&A

G&A at other companies

SSR MiningSSRM

$38.48M+61.0%

NNN REITNNN

$14.11M+8.4%

IPG PhotonicsIPGP

$36.09M+10.0%

QuantumScape Corporation QS

$24.61M-12.1%

Global Business Travel GroupGBTG

$98M+44.1%

Generate Biomedicines, Inc. GENB

$13.52M+33.3%

Other financials

Income statement

See full

Operating income-$27.5M-70.2%

Net income-$25.4M-93.6%

EPS (diluted)-$10.34-83.0%

Balance sheet

See full

Cash & equivalents$52.9M—

Total debt$5.3M—

Total equity-$115.6M-220%

Total assets$227.7M—

Cash flow

See full

Operating cash flow-$20.2M+0.2%

CapEx--100%

Free cash flow-$20.2M+0.4%

Valuation

See full

Market cap$972.65M—

Enterprise value$925.08M—

Returns & leverage

See full

Debt / equity-0×—

Current ratio13.2×—

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Seaport Therapeutics 's G&A?: Seaport Therapeutics (SPTX) reported G&A of $6.11M in Q1 2026.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.